WHO Guideline on the Use and Indications of GLP-1 Therapies for the Treatment of Obesity in Adults

·34 min·3 clips

The WHO issues its first guidelines on using GLP-1 drugs for obesity, but why are the recommendations only conditional?

This episode of JAMA Clinical Reviews features an interview about the World Health Organization's newly published living guidelines on GLP-1 therapies for obesity in adults. Host Dr. Kirsten Bibbins-Domingo, Editor-in-Chief of JAMA, is joined by Dr. Francesca Celletti, WHO Senior Advisor on Obesity, and Dr. Ezekiel Emanuel, Vice Provost at the University of Pennsylvania and a guideline evidence evaluator. The episode begins with an overview of the guidelines, which include two good practice statements and two conditional recommendations. The primary recommendation is for GLP-1 therapy in adults with BMI >30, combined with intensive behavioral interventions. Dr. Emanuel details the three main reasons the recommendations are conditional: limited study duration (mostly 6-24 months), most evidence coming from drug company trials, and incomplete data on broader health impacts like cardiovascular disease and addiction. A significant portion of the discussion focuses on the distinction between long-term and lifelong medication use, a critical unanswered question. Dr. Celletti explains the guideline currently recommends long-term use (beyond six months) but lacks data on discontinuation, maintenance dosing, and titration. Dr. Emanuel highlights specific concerns about side effects, notably that 25-40% of weight loss is muscle loss, which raises frailty risks, especially in older adults. The conversation explores the tension between pharmaceutical intervention and broader public health measures. Dr. Celletti emphasizes that GLP-1 therapy alone cannot solve obesity and must be part of a multi-faceted response including food and urban environment changes. Dr. Emanuel argues obesity is a social disease driven by environments that promote ultra-processed foods, and society must make healthy choices easier. The final major theme is equitable global access. Dr. Celletti outlines three barriers: high drug prices, health system readiness for chronic care delivery, and the need for universal health coverage to prevent out-of-pocket payments. Dr. Emanuel adds optimism about semaglutide patents expiring and over 40 new GLP-1 compounds in development, but warns of counterfeit drug risks. The episode concludes with takeaways: Dr. Celletti hopes GLP-1s can transform the epidemiological trajectory of non-communicable diseases, while Dr. Emanuel ranks GLP-1s among the top five biomedical breakthroughs since 2000 and stresses societal responsibility alongside clinical treatment.

As heard by us

WHO GLP-1 guidance meets unresolved clinical questions around microdosing, muscle mass, age, and frailty.

WHO guidance on GLP-1 therapies turns this episode into a useful check on how quickly clinical practice is adapting. JAMA Clinical Reviews keeps the focus measured, with Dr. Kirsten Bibbins-Domingo speaking with Dr. Francesca Celletti and Dr.

Read the full review in PlayNext →

Why you'd press play

Want to understand what GLP-1 guidance can and cannot settle before the clinic conversation gets complicated?

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from JAMA Clinical Reviews